SCHEMBL9890751

SCHEMBL9890751

CNC(=O)Cc1ccccc1-c1cccc(SC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.52
PTGER4 P35408 3/20 0.52
PTGER3 P43115 3/20 0.52
PTGER2 P43116 3/20 0.52
ALDH1A1 P00352 5/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
MAPT P10636 3/20 0.46
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
POLB P06746 3/20 0.42
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HPGD P15428 2/20 0.40
ENPP2 Q13822 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890746 0.83 PTGER1 (0.48) PTGER1PTGER4PTGER3PTGER2ALDH1A1
SCHEMBL2394292 0.82 FFAR1 (0.47) PTGER1PTGER4PTGER3PTGER2ALDH1A1
SCHEMBL2397419 0.81 KMT2A (0.51) ALDH1A1KMT2ACHRM1CHRM3HPGD
SCHEMBL2393439 0.81 SMN1; SMN2 (0.46) PTGER1PTGER4PTGER3PTGER2MEN1
SCHEMBL9890716 0.81 CHRM1 (0.62) PTGER1PTGER4PTGER3PTGER2CHRM1
SCHEMBL9890735 0.81 CHRM1 (0.44) PTGER1PTGER4PTGER3PTGER2ALDH1A1
SCHEMBL9890750 0.78 MTNR1A (0.54) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL2393347 0.77 RORC (0.48) ALDH1A1MEN1KMT2AMAPTAKR1C3
SCHEMBL2391528 0.74 PTGDR2 (0.51)
SCHEMBL24800434 0.73 PTGER1 (0.43) PTGER1PTGER4PTGER3PTGER2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGER1 1182/4885PTGER4 1681/4885PTGER3 1172/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGER1 1182/4885PTGER4 1681/4885PTGER3 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.